Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
Relmada Therapeutics, a clinical-stage biotech company focused on oncology and CNS therapies, announced it has been added to the Russell 2000 and Russell 3000 Indexes following the June 2026 reconstitution. This inclusion reflects the company's progress, supported by robust clinical data for its lead candidate NDV-01 and a strong financial position…